Glossary
MD&A (Management’s Discussion and Analysis): What It Must Contain and What Regulators Flag
MD&A, short for Management’s Discussion and Analysis, is the narrative report a public company files with its financial statements to explain, in management’s words, what drove the results, how it will fund itself and what could change. In Canada its content is set by Form 51-102F1 under National Instrument 51-102.
The financial statements show what happened. The MD&A explains why, and what the numbers mean for liquidity and the business plan. It accompanies required annual and interim financial reporting and is covered by CEO/CFO certification. The board approves annual MD&A and may delegate interim MD&A approval to the audit committee.
What does MD&A mean in accounting?
In accounting and securities reporting, MD&A is a required disclosure document, not a marketing letter. For a Canadian reporting issuer it is part of continuous disclosure under NI 51-102, which requires an MD&A for the annual financial statements and for each interim financial report.
US companies prepare a similar section under Item 303 of the SEC’s Regulation S-K (Item 7 of Form 10-K). The ideas overlap, but a Canadian issuer follows Form 51-102F1, and that is what Canadian regulators review against.
What must an MD&A contain under Form 51-102F1?
The form sets the headings. Venture issuers (generally those listed on the TSX Venture Exchange, or on the CSE other than its senior tier) get a few exemptions, marked below.
| Form 51-102F1 item | What it covers | Venture issuer note |
|---|---|---|
| 1.1 Date | Date of the MD&A | Same |
| 1.2 Overall performance | Overall performance and financial condition, including material impairments | Same |
| 1.3 Selected annual information | Key figures for recent years | Same |
| 1.4 Discussion of operations | What changed in revenue, costs and margins and why; significant projects without revenue | Without significant revenue, focus on spending and progress against milestones |
| 1.5 Summary of quarterly results | The eight most recently completed quarters | Same |
| 1.6 Liquidity | Ability to meet cash needs, working capital, defaults or covenant risk | Same |
| 1.7 Capital resources | Commitments for capital spending and how they will be funded | Same |
| 1.8 Off-balance sheet arrangements | Arrangements not on the balance sheet | Same |
| 1.9 Related party transactions | Who, what and the business purpose | Same |
| 1.10 Fourth quarter | Fourth-quarter events and adjustments | Same |
| 1.11 Proposed transactions | Pending asset or business acquisitions or dispositions | Same |
| 1.12 Critical accounting estimates | Analysis of key estimates | Not required for venture issuers |
| 1.13 Changes in accounting policies | Including initial adoption of new standards | Same |
| 1.14 Financial instruments | Nature, risks and how they are managed | Same |
| 1.15 Other MD&A requirements | Other items, including referenced information | Same |
| 2.1 to 2.3 Interim MD&A | Update of the annual MD&A for the quarter | May use shorter “quarterly highlights” (item 2.2.1) |
Source: Form 51-102F1 and NI 51-102, using the form consolidation dated July 25, 2023, checked in the original source review on October 7, 2026. The contractual obligations table under item 1.6 is also not required for venture issuers. Separately, NI 51-102 section 5.3 requires a venture issuer without significant revenue to break down exploration and evaluation, expensed R&D, development intangibles and general and administrative costs, by property for mining issuers, and section 5.4 requires outstanding share data.
When is MD&A filed?
MD&A must be filed by the same deadline as the financial statements it relates to, or with them if they are filed earlier (NI 51-102 section 5.1).
| Filing | Venture issuer | Non-venture issuer |
|---|---|---|
| Annual financial statements and MD&A | 120 days after year end | 90 days after year end |
| Interim financial report and MD&A | 60 days after quarter end | 45 days after quarter end |
Since March 19, 2026, an eligible venture issuer can use the CSA semi-annual reporting pilot (BCSC Coordinated Blanket Order 51-933) to skip the three and nine month interim report and MD&A. Eligibility includes listed securities, at least 12 months as a reporting issuer, revenue of no more than CAD 10 million on the latest audited statements, a clean filing record, and a news release. The six-month report and MD&A are still filed. Our issuer filing calendar lays these dates out for your year end.
What do regulators flag in MD&A?
Regulator findings make the form requirements more concrete. The CSA’s continuous disclosure review program and the OSC’s annual reports name MD&A problems in every recent edition:
Financial statements and MD&A were 21% of CSA issue-oriented reviews in fiscal 2024
(19% in fiscal 2023), behind only mining and oil and gas technical disclosure (CSA Staff Notice 51-365, November 2024).
58% of CSA review outcomes in fiscal 2024 required improved or amended disclosure, a refiling, or a missing document
(CSA, November 2024).
The OSC’s most common immediate actions in fiscal 2025 included refiling MD&A “where the form was materially deficient and did not meet the form requirements of Form 51-102F1”
(OSC Staff Notice 51-737, December 2025). In fiscal 2024 it also required MD&A refilings to fix non-GAAP measure disclosure (OSC 51-736).
The specific MD&A findings, by source:
| Finding | What the regulator expects | Source |
|---|---|---|
| Operations discussion is incomplete or boilerplate | Explain revenue, cost and margin changes, including labour, inflation and interest effects | CSA 51-365; OSC 51-736 |
| Liquidity lacks issuer-specific detail | Say how short and long term needs will be met, and address any default or covenant risk | CSA 51-365; OSC 51-736 |
| Forward-looking information unsupported or not updated | State material assumptions and risks; explain when results diverge from a published outlook | CSA 51-365; CSA 51-364; OSC 51-737 |
| Significant projects without timing or cost | Plan, milestones, spend to date, next costs, licences needed | CSA 51-364; OSC 51-736 |
| Venture issuer cost breakdown missing | Section 5.3 breakdown, property by property for mining | CSA 51-364; OSC 51-736 |
| Impairments and acquisitions not explained | Explain impairment drivers and what goodwill or intangibles represent | CSA 51-365 |
| Non-GAAP measures | Label, reconcile, and give no more prominence than the IFRS measure | CSA 51-364; OSC 51-736 |
These are risk-selected review outcomes, not the percentage of all issuers with deficient MD&A.
The CSA also reminds issuers that “quantity does not equal quality”. A longer MD&A that repeats the statements does not answer these comments.
How do you prepare an MD&A that holds up?
- Draft from the current working papers, not last quarter’s text. Every explanation should trace to a number in this period’s statements.
- Reconcile every figure in the MD&A to the financial statements before the draft circulates.
- Write the liquidity section as a plan: cash on hand, commitments, the funding source and what happens if it does not arrive.
- Update forward-looking statements made in earlier MD&As and news releases, and say what changed.
- Check non-GAAP and supplementary measures against NI 52-112 in the MD&A, the news release and any investor deck.
- Confirm venture issuer items: section 5.3 cost breakdown, outstanding share data and project milestones.
- Leave time for approval. The board approves the annual MD&A; it may delegate interim MD&A approval to the audit committee (NI 51-102 section 5.5). The CEO and CFO then file their certificates.
The semi-annual reporting order also includes conditions concerning sanctions, cease trade orders and earlier cessation of reliance during the preceding 12 months. Eligibility is tested at each relevant period end; a revenue threshold and current filings alone are insufficient.
Practitioner note
Treewalk’s public company team prepares interim and annual IFRS financial statements and MD&A, drafts CEO/CFO certificates and coordinates SEDAR+ filing for issuers on the TSX Venture Exchange and the CSE. The statements and MD&A are prepared together as one package so the narrative ties to the working papers. Treewalk does not audit or review financial statements and does not give legal advice; the approval stays with the company’s directors and officers. For recurring MD&A and statement preparation, see our public companies services.
Frequently asked questions
Is MD&A audited?
It is not covered by the financial-statement audit opinion. The auditor may have separate responsibilities for reading other information; that does not turn MD&A into audited financial statements. The external audit opinion covers the annual financial statements. The MD&A is approved by the board and certified by the CEO and CFO, which is why the internal reconciliation to the statements matters.
Do venture issuers have to file MD&A?
Yes. Venture issuers file annual and interim MD&A, but they can use quarterly highlights for interim periods, skip the critical accounting estimates section and the contractual obligations table, and, if eligible since March 2026, use the semi-annual reporting pilot.
What is the difference between MD&A and the financial statements?
The statements present the numbers and notes under the applicable accounting framework. Annual statements are audited; interim reports may be unreviewed by the auditor. The MD&A is management’s explanation of those numbers, the liquidity position and the outlook, in plain language.
What happens if MD&A is deficient or late?
A regulator can require prospective changes or a refiling, and in the OSC’s case refilers are listed on its Refilings and Errors List. Failing to file on time can lead to a cease trade order.
Is this legal advice?
No. It summarizes NI 51-102, Form 51-102F1 and published regulator guidance as of October 2026. Confirm how they apply to your company with securities counsel.
NI 51-102 can require earlier annual or interim filing when the corresponding statements are filed in a foreign jurisdiction. The 120-day and 60-day venture deadlines are not permission to wait after an earlier foreign filing.
Where to next
Plan the next cycle with the issuer filing calendar, then read how SEDAR+ filing support and IFRS financial statement preparation fit around the MD&A. To talk about a filing, contact us or see our public companies page.
